Clinical Pharmacology & Biopharmaceutics
Open Access

Abstract

The hypothalamic PRP-1 produced in NSO and NPO possesses multiple pharmacological properties: Immunomodulator, antibacterial and antiviral, antitumor, neuroprotective including recently discovered cerebrovascular effects and anticoagulation activity of PRP-1 underlay the investigation of its role on platelet aggregation mapping process. The antiplatelet property of PRP-1 was demonstrated on ADP-tem induced method using ROTEM platelet system. The healthy volunteers (n=22) aged 20-35 were involved in the experiment. The statistical analysis was performed using ANOVA test. Obtained results demonstrate that the incubation of PRP-1 (in concentration 0.024 �?¼g/�?¼l) with blood samples characterized by standard parameters of aggregation process (A6, MS and AUC) did not induce any significant changes on platelet aggregation process after ADP-tem initiation. In spite of this, incubation of PRP-1 with blood samples characterized by high level of aggregation process parameters leads to prevention of ADP induced aggregation which is appeared by decreasing of A6, MS and AUC levels for 52%, 62% and 55,6% (p<0.01) accordingly. In case of PRP-1 incubation with blood samples characterized by low level of baseline aggregation process parameters leads to increasing of A6, MS and AUC values for 58.5%, 85.1% and 93.9% accordingly. It is noticeable that in both cases (blood samples with low and high level of aggregation process parameters) PRP-1 incubation turns the platelet aggregation parameters level into direction leading to their standard values. Thus, the presented investigation indicates that PRP-1 possesses regulatory role on aggregation process. These data could be served for design and development of novel antiplatelet agents based on PRP-1 structure.

Biography

Emma Yeritsyan is currently a PhD student at the Yerevan State Medical University. She has obtained her Bachelor’s and Master’s degree from the Faculty of Pharmacy, Yerevan State Medical University. She has also worked at the Scientific Center of Drug and Medical Technology Expertise as an Expert. She has published more than 15 papers in scientific journals and has also participated in several conferences.

Email: emmayeritsyan@gmail.com